CD226 and neoplasm: Additional mechanisms responsible for DNAM-1 hypo-functionality in advanced tumors comprise post-translational ligand modifications or the release of ligands as soluble forms, with a consequent reduction of their expression on the surface of tumor cells (Figure 2B).